C. Bello

发表

conventional therapy for the disease or resistant acute myeloid leukemia (AML) or not amenable to A phase 1 study of SU11248 in the treatment of patients with refractory

J. Cherrington, W. Berdel, O. Ottmann, 2013 .

Pharmacokinetics, Modeling, and Simulation in the Development of Sunitinib Malate: A Case Study

B. Houk, C. Bello, 2011 .

Blood-Based Biomarkers of SU11248 Activity and Clinical Outcome in Patients with Metastatic Imatinib-Resistant Gastrointestinal Stromal Tumor

J. Manola, J. Desai, J. Folkman, 2007, Clinical Cancer Research.

Effect of rifampin on the pharmacokinetics of SU11248 in healthy volunteers

B. Houk, S. Misbah, J. Smeraglia, 2005 .

Pharmacodynamic analysis of target receptor tyrosine kinase activity and apoptosis in GIST tumors responding to therapy with SU11248

J. Desai, G. Demetri, J. Heymach, 2005 .

A phase I, open-label, mass balance study of [14C] dacomitinib (PF-00299804) in healthy male volunteers

G. Ni, C. Loi, C. Alvey, 2013, Cancer Chemotherapy and Pharmacology.

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.

H. Rugo, A. Wolff, H. Burstein, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Investigation of the impact of hepatic impairment on the pharmacokinetics of dacomitinib

J. Masters, Yali Liang, A. Płotka, 2015, Investigational New Drugs.

Effect of food or proton pump inhibitor treatment on the bioavailability of dacomitinib in healthy volunteers

J. Masters, R. Labadie, Yali Liang, 2016, Journal of clinical pharmacology.

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

John Smeraglia, R. Motzer, M. Michaelson, 2007, Journal of Translational Medicine.

Pharmacokinetics and Safety of Sunitinib Malate in Subjects With Impaired Renal Function

S. Swan, T. Marbury, M. Toh, 2010, Journal of clinical pharmacology.

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

E. Raymond, C. Robert, J. Armand, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.

M. Heinrich, J. Cherrington, R. Paquette, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.

Randy Allred, Hubert Serve, Wolfgang E Berdel, 2005, Blood.

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

Xin Huang, J. Desai, G. Demetri, 2006, The Lancet.

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis

G. Demetri, R. Motzer, B. Houk, 2010, Cancer Chemotherapy and Pharmacology.

Sunitinib malate for the treatment of solid tumours: a review of current clinical data

R. Motzer, J. Christensen, C. Bello, 2006, Expert opinion on investigational drugs.

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.

R. Figlin, R. Motzer, M. Michaelson, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Electrocardiographic Characterization of the QTc Interval in Patients with Advanced Solid Tumors: Pharmacokinetic- Pharmacodynamic Evaluation of Sunitinib

Xin Huang, C. Baum, L. Rosen, 2009, Clinical Cancer Research.

Pharmacokinetics, Distribution, and Metabolism of [14C]Sunitinib in Rats, Monkeys, and Humans

W. Pool, E. Wu, Ping Kang, 2012, Drug Metabolism and Disposition.

Pharmacokinetics of sunitinib malate in subjects with hepatic impairment

J. Smeraglia, L. Sherman, M. Toh, 2010, Cancer Chemotherapy and Pharmacology.

Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib Failure

A. D. Van den Abbeele, C. Antonescu, J. Fletcher, 2009, Clinical Cancer Research.

A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients

Dongwoo Kang, Brett E. Houk, B. Houk, 2009, Clinical Cancer Research.

Clinical Development of Sunitinib Malate

I. Chen, C. Bello, Z. Aguilar, 2008 .

A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period

F. Kabbinavar, C. Baum, C. Britten, 2008, Cancer Chemotherapy and Pharmacology.

A phase I open‐label study to investigate the potential drug–drug interaction between single‐dose dacomitinib and steady‐state paroxetine in healthy volunteers

R. Labadie, G. Ni, N. Richie, 2014, Journal of clinical pharmacology.

The effect of dacomitinib (PF-00299804) on CYP2D6 activity in healthy volunteers who are extensive or intermediate metabolizers

R. Labadie, G. Ni, C. McCormick, 2012, Cancer Chemotherapy and Pharmacology.

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

J. Desai, G. Demetri, J. Verweij, 2006, The Lancet.

Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species

Qingling Zhang, J. Sukbuntherng, J. Haznedar, 2009, Cancer Chemotherapy and Pharmacology.

Changing Body Weight–Based Dosing to a Flat Dose for Avelumab in Metastatic Merkel Cell and Advanced Urothelial Carcinoma

Akash Khandelwal, P. Girard, J. Wade, 2019, Clinical pharmacology and therapeutics.

Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects

John Smeraglia, J. Smeraglia, L. Sherman, 2006, Anti-cancer drugs.

Surrogate biomarkers in evaluating response to anti-angiogenic agents: focus on sunitinib.

S. Deprimo, C. Bello, SE DePrimo, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

EGFR status and daily dose: Effect on tumor growth inhibition in cancer patients treated with dacomitinib (PF-00299804).

P. Jänne, Keunchil Park, N. Yamamoto, 2012 .

Receptor Tyrosine Kinase Activity and Apoptosis in Gastrointestinal Stromal Tumors: a Pharmacodynamic Analysis of Response to Sunitinib Malate (SU11248) Therapy

J. Desai, G. Demetri, S. George, 2005 .

Levels of circulating endothelial cells (CECs) and monocytes as pharmacodynamic markers of SU11248 activity in patients (pts) with metastatic imatinib-resistant GIST

J. Manola, J. Desai, G. Demetri, 2005 .

A phase I mass-balance study to evaluate the metabolism and excretion of [14C]-sunitinib (SU11248) in healthy male subjects

J. Smeraglia, L. Sherman, M. Garrett, 2007 .

Sunitinib pharmacokinetic (PK) and safety data in subjects with renal impairment and on hemodialysis

M. Toh, G. Ni, R. Khosravan, 2008 .

Exposure–response relationships in patients with metastatic renal cell carcinoma receiving sunitinib: maintaining optimum efficacy in clinical practice

A. Ravaud, C. Bello, 2011, Anti-cancer drugs.

Time‐Varying Clearance and Impact of Disease State on the Pharmacokinetics of Avelumab in Merkel Cell Carcinoma and Urothelial Carcinoma

Y. Vugmeyster, Akash Khandelwal, P. Girard, 2019, CPT: pharmacometrics & systems pharmacology.

Abstract CT208: Absolute bioavailability of dacomitinib (PF-00299804): Comparison of oral and intravenous administration in healthy volunteers

R. Labadie, Yali Liang, N. Giri, 2014 .

Influence of mild and moderate hepatic impairment on the pharmacokinetics (PK) of the pan-HER inhibitor dacomitinib.

J. Masters, Yali Liang, G. Ni, 2013 .

Exposure-response of sunitinib in metastatic renal cell carcinoma (mRCC): A population pharmacokinetic/pharmacodynamic (PKPD) approach

R. Motzer, M. Michaelson, B. Redman, 2007 .

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis

G. Demetri, R. Motzer, B. Houk, 2010, Cancer Chemotherapy and Pharmacology.

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.

H. Döhner, J. Cherrington, D. Hossfeld, 2005, Blood.

Pharmacokinetics, Distribution, and Metabolism of [14C]Sunitinib in Rats, Monkeys, and Humans

W. Pool, E. Wu, Ping Kang, 2012, Drug Metabolism and Disposition.

Species distribution and antimicrobial susceptibility of gram-negative aerobic bacteria in hospitalized cancer patients

R. Motzer, M. Michaelson, B. Rini, 2009, Journal of Translational Medicine.

Population pharmacokinetics of sunitinib in Japanese and Western healthy volunteers, solid tumor, metastatic renal cell carcinoma (MRCC) and imatinib-resistant or -intolerant gastrointestinal stromal tumors (GIST) patients

B. Houk, M. Amantea, C. Bello, 2008 .